# Dalfampridine for Imbalance in Multiple Sclerosis

> **NCT01444300** · PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis
- Fatigue

## Interventions

- **DRUG:** Dalfampridine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01444300
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444300, "Dalfampridine for Imbalance in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01444300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*